Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - agomelatine, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; stearic acid; colloidal anhydrous silica; sodium starch glycollate type a; maize starch; lactose monohydrate; propylene glycol; butan-1-ol; ethanol; isopropyl alcohol; shellac; strong ammonia solution; indigo carmine aluminium lake; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; glycerol - treatment in adults of: - of major depression (mdd) including prevention of relapse - generalised anxiety disorder (gad)

Singapore - English - HSA (Health Sciences Authority)

servier (s) pte ltd - agomelatine - tablet, film coated - 25 mg - agomelatine 25 mg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company ireland - 28's (14's blister x 2) - tablet - 25mg/tablets - central nervous system-antidepressants

Namibia - English - Namibia Medicines Regulatory Council

servier laboratories industries (pty) ltd - agomelatine - tablet - each tablet contains; agomelatine 25,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (australia) pty ltd - agomelatine -

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - agomelatine - depressive disorder, major - psychoanaleptics, - treatment of major depressive episodes in adults.,

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 90.6 mg (equivalent: ziprasidone, qty 80 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; pregelatinised maize starch; lactose monohydrate; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 67.95 mg (equivalent: ziprasidone, qty 60 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; lactose monohydrate; titanium dioxide; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 45.3 mg (equivalent: ziprasidone, qty 40 mg) - capsule, hard - excipient ingredients: magnesium stearate; indigo carmine; titanium dioxide; lactose monohydrate; pregelatinised maize starch; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ziprasidone hydrochloride monohydrate, quantity: 22.65 mg (equivalent: ziprasidone, qty 20 mg) - capsule, hard - excipient ingredients: titanium dioxide; pregelatinised maize starch; indigo carmine; gelatin; lactose monohydrate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zeldox (ziprasidone) is indicated for: (i) the treatment of schizophrenia, related psychoses, prevention of relapse and for maintenance of clinical improvement during continuation therapy; and (ii) as monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar i disorder.